// App-Quantinova.ai

1747 : FDA-Approved Ruxolitinib in Patients with Myelofibrosis: the Stanford Experience

Researchers

Presenter

  • Anh Pham

Principal Investigators

  • Cecelia Perkins

  • Andrea Linder

  • Lenn Fechter

  • Jason Gotlib

Medical Centers

  • Pediatric Immunology, Stanford University School of Medicine, Stanford, CA

  • Pediatric Immunology, Stanford University School of Medicine, Stanford, CA

  • Stanford School of Medicine, Stanford, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Thrombocytopenia

  • Myelofibrosis

  • Anemia

Biomarkers

  • Alanine transaminase

  • MPL proto-oncogene, thrombopoietin receptor

  • Aspartate aminotransferase

  • Circulating tumor cells

  • Janus kinase

  • Red Blood Cells

Drug/Treatment

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved